戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ty of the bovine bc1 complex (Ki = 80 nm) to atovaquone.
2 erential sensitivity of these two species to atovaquone.
3 e bc(1) complexes resistant to inhibition by atovaquone.
4 or this study we focus on the anti-malarial, atovaquone.
5 new antimalarial agents: 5-fluoroorotate and atovaquone.
6 line and a broad spectrum antiparasitic drug atovaquone.
7 an endochin-like quinolone (ELQ) prodrug and atovaquone.
8 fected patients receiving treatment doses of atovaquone.
9 to established antimalarials chloroquine and atovaquone.
10 ng clinical isolates harboring resistance to atovaquone.
11  cross-resistance with the antimalarial drug atovaquone.
12 that are resistant to the anti-malarial drug atovaquone.
13 intaining little to no cross-resistance with atovaquone.
14 sensitivity of the cytochrome bc1 complex to atovaquone.
15 ve either enhanced or reduced sensitivity to atovaquone.
16 developed in 122 of 536 patients assigned to atovaquone (15.7 cases per 100 person-years), as compare
17 mg twice daily (BID) for 14 days followed by atovaquone 1500 mg BID for 14 days, or vice-versa, with
18 open-label, randomized trial comparing daily atovaquone (1500-mg suspension) with daily dapsone (100
19 0 subjects receiving EFV in combination with atovaquone 750 mg BID achieved an atovaquone C avg>18.5
20 ggest that the currently recommended dose of atovaquone 750 mg BID for treatment of mild to moderate
21 of 10 subjects receiving EFV-based cART plus atovaquone 750 mg BID had an atovaquone C avg>15 microg/
22           Subjects were randomly assigned to atovaquone 750 mg twice daily (BID) for 14 days followed
23 The subjects were assigned to receive either atovaquone (750 mg every 12 hours) and azithromycin (500
24                                              Atovaquone, a 2-hydroxynaphthoquinone, is a competitive
25 roximately 200 fold) than that observed with atovaquone, a licensed bc(1)-specific antimalarial drug.
26 t parasites with different concentrations of atovaquone, a mitochondrial inhibitor, the recovery of d
27                                Resistance to atovaquone, a second-line agent, may also be developing.
28                                              Atovaquone, a ubiquinone analogue, targets C. felis cyto
29 etermine the pharmacokinetics of aerosolized atovaquone (administered with and without a synthetic su
30 llowing dose regimens: (1) 250 milligrams of atovaquone and 100 milligrams of proguanil (250/100 mill
31  milligrams on day -7, (4) 500 milligrams of atovaquone and 200 milligrams of proguanil (500/200 mill
32 igrams) on day -7 or, (5) 1000 milligrams of atovaquone and 400 milligrams of proguanil (1000/400 mil
33 with this protocol, such as the antimalarial Atovaquone and antitheilerial Parvaquone, thus evidencin
34                          Treatment combining atovaquone and azithromycin (A&A) has been associated wi
35  that infects domestic cats, is treated with atovaquone and azithromycin (A&A).
36  therapy in 65 percent of those who received atovaquone and azithromycin and 73 percent of those who
37 or the treatment of babesiosis, a regimen of atovaquone and azithromycin is as effective as a regimen
38                 We describe the emergence of atovaquone and azithromycin resistance associated with m
39         The most common adverse effects with atovaquone and azithromycin were diarrhea and rash (each
40 d by 15 percent of the subjects who received atovaquone and azithromycin, as compared with 72 percent
41                         In vitro response to atovaquone and cytochrome b sequence of clinical isolate
42 nnot tolerate trimethoprim-sulfamethoxazole, atovaquone and dapsone are similarly effective for the p
43 ith chloroquine resistance, a combination of atovaquone and proguanil or quinine plus tetracycline or
44                     These findings establish atovaquone as a novel, clinically accessible STAT3 inhib
45                     Six cases were receiving atovaquone as a prophylaxis.
46 ation because of adverse events was 3.78 for atovaquone as compared with dapsone (95 percent confiden
47 potency equal to that of orally administered atovaquone at 10 mg/kg.
48 l antimalarial agents acquired resistance to atovaquone at high frequency, but not to 5-fluoroorotate
49                   The antitoxoplasmosis drug atovaquone, at a very low concentration (0.03 microM), t
50   Impressively, a combination of ELQ-334 and atovaquone, at doses as low as 5.0 mg/kg each, resulted
51 ceiving EFV-based cART had 47% and 44% lower atovaquone AUCtau than subjects not receiving cART at at
52 dose by aerosol, mean peak concentrations of atovaquone averaged 52 microg/mL in plasma and 31 microg
53 abesiosis consists of two drug combinations, atovaquone + azithromycin or quinine + clindamycin.
54 of the changes in cytochrome b structure and atovaquone binding with the mutated bc(1) complexes prov
55  of the amino acid side-chains may determine atovaquone-binding affinity, and thereby selective toxic
56 e, including amino acid substitutions in the atovaquone-binding regions of cytochrome b (cytb) and th
57 ovide the first molecular description of how atovaquone binds to the bc1 complex and explain the diff
58                  These results indicate that atovaquone binds to the ubiquinol oxidation pocket of th
59                           Here, we show that atovaquone blocks this domain movement by locking the ir
60 based cART plus atovaquone 750 mg BID had an atovaquone C avg>15 microg/mL, which has previously been
61 ation with atovaquone 750 mg BID achieved an atovaquone C avg>18.5 microg/mL, a concentration that ha
62 que metabolic signatures were also found for atovaquone, chloroquine, proguanil, cycloguanil and meth
63                        We observed that only atovaquone collapsed DeltaPsim and inhibited parasite re
64 ge for future clinical evaluation of ELQ and atovaquone combination therapy for treatment of human ba
65  in 33% of isolates from patients exposed to atovaquone, compared with 6% from those who were not (P=
66 ructural basis for the selective toxicity of atovaquone could help in designing drugs against infecti
67 azole, with second-line therapies, including atovaquone, dapsone, and pentamide.
68 me b, the sensitivity of the yeast enzyme to atovaquone decreased (Ki = 100 nm) with no loss in activ
69 e AUCtau than subjects not receiving cART at atovaquone doses of 750 mg BID and 1500 mg BID, respecti
70                                 In addition, atovaquone eradicates hypoxia in FaDu, HCT116 and H1299
71                                              Atovaquone exposure (area under the curve) during liver
72 re common in patients with AIDS and PCP with atovaquone exposure, but the clinical significance of th
73 posure were matched with 45 patients with no atovaquone exposure.
74  carinii pneumonia (PCP) are associated with atovaquone exposure.
75 ng on the reduction of cross-resistance with atovaquone for activity against the clinical isolates W2
76 c stem cell transplantation, extended use of atovaquone for Pneumocystis prophylaxis was associated w
77                                 Furthermore, atovaquone had no effect on mammalian DeltaPsim.
78  the field, greatly enhancing the utility of atovaquone in malaria control.
79                                Resistance to atovaquone in the field is associated with point mutatio
80 ant) and to evaluate the efficacy of inhaled atovaquone in the prevention and treatment of Pneumocyst
81 val of rats with PCP and, when combined with atovaquone, increased plasma and lung concentrations of
82             In these enzymes, the IC(50) for atovaquone increases from 25 nm for the enzyme from wild
83                        In malaria parasites, atovaquone inhibits mitochondrial electron transport at
84                                              Atovaquone inhibits respiration in target organisms by s
85 utinely achieved clinically in human plasma, atovaquone inhibits STAT3 phosphorylation, the expressio
86                                              Atovaquone inhibits the bc1 complex competitively with a
87                                              Atovaquone is a substituted 2-hydroxynaphthoquinone that
88                                              Atovaquone is a substituted hydroxynaphthoquinone that i
89                                              Atovaquone is a substituted hydroxynaphthoquinone that i
90                                              Atovaquone is a ubiquinone analogue, and decreases the O
91                                              Atovaquone is an anti-malarial drug used in combination
92                                              Atovaquone is an antiparasitic drug that selectively inh
93  However, among those not receiving dapsone, atovaquone is better tolerated and may be the preferred
94 t a 7- to 10-day course of azithromycin plus atovaquone is effective for mild babesiosis.
95                                              Atovaquone is not a kinase inhibitor but instead rapidly
96  to a commonly used antimalarial medication, atovaquone, is apparently unable to spread.
97    A computed energy-minimized structure for atovaquone liganded to the yeast bc1 complex suggests th
98 oelii; these mutants exhibited resistance to atovaquone-mediated collapse of mitochondrial membrane p
99 expression signature of STAT3, we discovered atovaquone (Mepron), an antimicrobial approved by the US
100                                              Atovaquone (Mepron, 566c80) is an effective agent agains
101 lysis of recrudescent parasites after ELQ or atovaquone monotherapy identified genetic substitutions
102 roviral therapy (cART) impacted steady-state atovaquone plasma concentrations in human immunodeficien
103         A promising alternative treatment is atovaquone plus azithromycin.
104                                              Atovaquone pressure selects parasites with mutations in
105 artesunate-amodiaquine (2.9%) and artesunate-atovaquone-proguanil (1.0%) groups.
106           An additional group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1
107 (cohort 1A), six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and
108 oral regimen only (95 AL, 162 mefloquine, 36 atovaquone-proguanil [AP], and 17 others), and 87 were a
109 M265 1 day before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas plac
110 Indonesia or Papua New Guinea, in which case atovaquone-proguanil is best, with mefloquine or quinine
111                                  Single-dose atovaquone-proguanil provides effective malaria chemopro
112 re observed after artesunate-amodiaquine and atovaquone-proguanil therapies, respectively.
113 ble-blind trial to establish the efficacy of atovaquone-proguanil to prevent malaria with the goal of
114 iaquine, atovaquone-proguanil, or artesunate-atovaquone-proguanil treatment groups and followed for 2
115                                   Artesunate-atovaquone-proguanil was a highly effective alternative
116                                              Atovaquone-proguanil was characterized by a slow blood s
117                                   Artesunate-atovaquone-proguanil was not associated with any failure
118 istance, few alternative non-ACTs, including atovaquone-proguanil, are currently available.
119 randomly assigned to artesunate-amodiaquine, atovaquone-proguanil, or artesunate-atovaquone-proguanil
120                        Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an in
121                   However, the proportion of atovaquone-proguanil-treated patients with positive smea
122 also resistant to the synergistic effects of atovaquone/ proguanil combination.
123                                              Atovaquone/proguanil was the most commonly prescribed an
124 ochrome b genes from 2 of 4 patients who had atovaquone prophylaxis failure contained mutations resul
125               Fifteen patients with previous atovaquone prophylaxis or treatment exposure were matche
126 nce of PCP was significantly associated with atovaquone prophylaxis.
127                                              Atovaquone rapidly decreases the OCR by more than 80% in
128 dertaking clinical studies to assess whether atovaquone reduces tumour hypoxia in patients, thereby i
129                                              Atovaquone represents a class of antimicrobial agents wi
130 f this class to overcome parasite Q(o)-based atovaquone resistance and provides critical structural i
131                         Based on our malaria atovaquone resistance data, a series of cytochrome b mut
132               To assess the possibility that atovaquone resistance might be developing, the genes for
133  To better understand the molecular basis of atovaquone resistance, we have introduced seven of the m
134 ative explanation for the molecular basis of atovaquone resistance.
135 e and cytochrome b sequence did not indicate atovaquone resistance.
136 viding direct proof that the mutation causes atovaquone resistance.
137 cular and biochemical characterization of an atovaquone-resistant field isolate, TM902CB.
138     To that end, we derived nine independent atovaquone-resistant malaria parasite lines by suboptima
139  have introduced seven of the mutations from atovaquone-resistant P. jirovecii into the cytochrome b
140 levels of expression, compared with the 3D7 (atovaquone-sensitive) control strain in bc(1) and cytoch
141                           This suggests that atovaquone, shown to inhibit mitochondrial electron tran
142                                              Atovaquone targets parasite cytochrome b.
143  parasites rendered the complex resistant to atovaquone, thereby providing direct proof that the muta
144                   The administration of oral atovaquone to mice inhibited tumor growth and prolonged
145               The recent, growing failure of atovaquone treatment and increased mortality of patients
146                               The failure of atovaquone treatment and mortality of patients with mala
147        These effects were also observed with atovaquone treatment of primary blasts isolated from pat
148 se of reactive oxygen species resulting from atovaquone treatment.
149 ases per 100 person-years; relative risk for atovaquone vs. dapsone, 0.85; 95 percent confidence inte
150                                         When atovaquone was combined with surfactant, mean peak conce
151                                              Atovaquone was shown to inhibit the respiratory chain of
152  50% growth inhibition, while the IC(50) for atovaquone (which does not inhibit FPPS) remained the sa
153  shift of the inhibitory constant (K(i)) for atovaquone with a concomitant reduction in the V(max) of
154 ogates to model the molecular interaction of atovaquone with human and resistant pathogen enzymes.
155          We have examined the interaction of atovaquone with the bc1 complex isolated from Saccharomy

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top